THERABLAST MAXIMUM RELIEF

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: THERABLAST MAXIMUM RELIEF
Generic name: LIDOCAINE, MENTHOL
Manufacturer: Releaf Technologies LLC
Product type: HUMAN OTC DRUG
SPL set ID: 09809985-3a88-9bb7-e063-6394a90a2f5f
SPL ID: 2b3a9786-358b-6c49-e063-6294a90a5d93
Version: 2
Effective date: 2025-01-08
Source export date: 2026-10-12
Source partition: 12
Source file: https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-10-12/edd23646015c9adc800cdbe2b778398a2d2b70e90dce5721ef2b191499a0397f/drug-label-0012-of-0014.json.zip
Source manifest SHA-256: 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run: 20261013T011858Z
Imported at: 2026-10-13 02:53:18

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application number		M017	openfda.application_number
brand name		THERABLAST MAXIMUM RELIEF	openfda.brand_name
generic name		LIDOCAINE, MENTHOL	openfda.generic_name
manufacturer name		Releaf Technologies LLC	openfda.manufacturer_name
ndc	package	78663-201-34	openfda.package_ndc
ndc	product	78663-201	openfda.product_ndc
ndc11	package	78663020134	derived:openfda.package_ndc
spl id		2b3a9786-358b-6c49-e063-6294a90a5d93	id
spl set id		09809985-3a88-9bb7-e063-6394a90a2f5f	set_id
unii		98PI200987	openfda.unii
unii		L7T10EIP3A	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNING For external use only. Do not use large quantities, particularly over raw surfaces or blistered areas. When using this product avoid contact with the eyes. Stop using and ask a doctor if the condition worsens symptoms persist for more than 7 days symptoms clear up and occur again within a few days a rash or irritation develops.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.